PHILADELPHIA and OXFORDSHIRE, United Kingdom, Oct. 21, 2021 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in cell therapy to treat cancer, will report financial results and
These two novel-drug makers could be top takeover targets next year.
- Clinical update and translational data from SPEARHEAD-1 in patients with synovial sarcoma and MRCLS to be presented at CTOS -
Adaptimmune Therapeutics has a diverse pipeline focused on TCR-engineered T cells. Their most advanced candidate, afamitresgene autoleucel, will likely receive approval.
Adaptimmune (ADAP) is seeing positive earnings estimate revisions, suggesting that it could be a solid choice for investors.
Profit-taking seemed to be the general dynamic behind the biotech's 14% slide.
Adaptimmune Therapeutics plc (NASDAQ: ADAP) has announced updated data from its Phase 1 SURPASS trial in multiple solid tumors evaluating ADP-A2M4CD8. ADP-A2M4CD8 is a next-generation T-cell therap

ADAP Stock: Why It Increased Today

08:02am, Monday, 13'th Sep 2021
The stock price of Adaptimmune Therapeutics PLC (NASDAQ: ADAP) increased by over 10% pre-market today. This is why it happened.
- Confirmed complete response in ovarian cancer, and confirmed partial responses in ovarian, head and neck, esophagogastric junction, bladder, and synovial sarcoma cancers -
Adaptimmune (ADAP) shares jump on a collaboration and license agreement with Roche for the development of allogeneic T-cell therapies for up to five shared cancer targets.

ADAP Stock: 28.95% Increase Explanation

04:19pm, Tuesday, 07'th Sep 2021
The stock price of Adaptimmune Therapeutics PLC (NASDAQ: ADAP) increased 28.95% today. This is why it happened.
A major licensing deal with cancer giant Roche is pushing the biotech's shares higher this morning.
Adaptimmune Therapeutics plc (NASDAQ: ADAP) has announced a collaboration and license agreement with Genentech, a unit of Roche Holdings AG (OTC: RHHBY), to develop and commercialize allogeneic
- Combining both companies' cell therapy leadership and expertise, the collaboration covers the research and development of “off-the-shelf” cell therapies for up to five shared cancer targets and
Adaptimmune (ADAP) announces encouraging data from an early-stage study on liver cancer patients from its cell therapy candidate.
Click to get the best stock tips daily for free!

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE